Shares of Park Ha Biological Technology slid another 8% to $1.15 on June 25, extending a steep pullback that has now erased much of the gains from a multi-day spike triggered by the company's strategic partnership with Cloud Factory Technology Holdings. The stock peaked near $1.38 on June 23 before falling 9.42% the following day, and today's decline signals that traders who rode the AI buzz are heading for the exits.

  • The Rally Was Built on Announcement Hype, Not Revenue — BYAH's partnership with Cloud Factory Technology Holdings, an AI-focused firm, ignited speculative buying in a stock that trades in the penny-stock range around $1 to $1.25. But Park Ha Biological Technology is fundamentally a biotech company, and no details have emerged showing how an AI tie-up translates into near-term sales or profit. Without concrete revenue projections or product timelines, the rally relied entirely on sentiment — the most fragile fuel a stock can burn.

  • The Pullback Follows a Textbook Pattern for Low-Float Stocks — Micro-cap stocks (companies worth very little on the open market) like BYAH are prone to violent swings because a relatively small number of shares trade hands each day. That thin trading volume means a burst of buying can push the price up fast, but the same dynamic works in reverse. The stock has now fallen roughly 17% from its $1.38 high in just two sessions, illustrating how quickly momentum evaporates when early buyers cash out.

  • The $1.20–$1.25 Zone Is the Real Test — Before the partnership news, BYAH traded steadily between $1.00 and $1.25. The stock is now sliding back into that range, and whether it stabilizes here or breaks below $1.20 will reveal how much lasting value — if any — the market assigns to the Cloud Factory deal. A close below $1.20 would suggest the partnership added zero durable premium to the stock.

  • Shareholders Need Execution Details, Not Press Releases — For the AI partnership to matter beyond a single week's trading, management must articulate specific milestones: what technology is being developed, what market it targets, and when it could generate income. Until that happens, BYAH remains a speculative biotech name that briefly caught an AI tailwind — a temporary boost from investor excitement around artificial intelligence — and is now giving it back.